Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCTH Delcath Systems	$11.09 +1.9%	$12.74	$7.17 ▼ $18.23	$387.44M	0.82	581,327 shs	406,606 shs
MBOT Microbot Medical	$3.00 -4.0%	$2.61	$0.82 ▼ $3.38	$108.92M	1.15	3.07 million shs	1.33 million shs
OM Outset Medical	$13.02 +2.8%	$18.39	$5.85 ▼ $25.35	$232.61M	2.14	228,763 shs	112,857 shs
TMCI Treace Medical Concepts	$6.94 +6.3%	$5.83	$4.54 ▼ $10.79	$439.35M	0.68	396,103 shs	368,240 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCTH Delcath Systems	+3.52%	+3.42%	-4.06%	-29.67%	+45.65%
MBOT Microbot Medical	+7.96%	+8.33%	+19.08%	+26.83%	+219.05%
OM Outset Medical	+1.93%	-10.14%	-34.66%	-31.51%	-4.03%
TMCI Treace Medical Concepts	+2.19%	+16.82%	+8.83%	-2.83%	+14.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DCTH Delcath Systems	2.8183 of 5 stars	3.5	2.0	3.0	2.5	0.6
MBOT Microbot Medical	1.8462 of 5 stars	3.5	1.0	3.2	0.0	0.6
OM Outset Medical	1.7008 of 5 stars	3.5	2.0	2.1	0.8	0.0
TMCI Treace Medical Concepts	2.2557 of 5 stars	3.2	1.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DCTH Delcath Systems	3.00	Buy	$24.50	121.02% Upside
MBOT Microbot Medical	3.00	Buy	$9.00	200.50% Upside
OM Outset Medical	3.00	Buy	$24.67	89.45% Upside
TMCI Treace Medical Concepts	2.33	Hold	$9.83	41.69% Upside

Current Analyst Ratings Breakdown

Latest MBOT, DCTH, TMCI, and OM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	TMCI Treace Medical Concepts	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$8.60 ➝ $6.50
8/8/2025	TMCI Treace Medical Concepts	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $6.00
8/7/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $31.00
8/7/2025	OM Outset Medical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $22.00
7/14/2025	OM Outset Medical	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$37.00
6/23/2025	DCTH Delcath Systems	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
5/23/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $29.00
5/21/2025	OM Outset Medical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$14.00 ➝ $21.00
5/15/2025	OM Outset Medical	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DCTH Delcath Systems	$37.21M	10.42	N/A	N/A	$3.00 per share	3.70
MBOT Microbot Medical	N/A	N/A	N/A	N/A	$0.17 per share	N/A
OM Outset Medical	$113.69M	2.04	N/A	N/A	$8.50 per share	1.53
TMCI Treace Medical Concepts	$209.36M	2.09	N/A	N/A	$1.55 per share	4.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DCTH Delcath Systems	-$26.39M	$0.05	221.52	N/A	N/A	3.18%	6.91%	5.80%	N/A
MBOT Microbot Medical	-$11.44M	-$0.65	N/A	N/A	N/A	N/A	-110.27%	-94.20%	8/13/2025 (Estimated)
OM Outset Medical	-$127.98M	-$20.29	N/A	∞	N/A	-82.06%	-97.17%	-32.84%	N/A
TMCI Treace Medical Concepts	-$55.74M	-$0.79	N/A	N/A	N/A	-23.01%	-46.76%	-23.35%	N/A

Latest MBOT, DCTH, TMCI, and OM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MBOT Microbot Medical	-$0.08	-$0.10	-$0.02	-$0.10	$1.00 million	N/A
8/7/2025	Q2 2025	TMCI Treace Medical Concepts	-$0.29	-$0.28	+$0.01	-$0.28	$47.08 million	$47.39 million
8/6/2025	Q2 2025	DCTH Delcath Systems	$0.02	$0.07	+$0.05	$0.07	$22.84 million	$24.16 million
5/21/2025	Q1 2025	MBOT Microbot Medical	-$0.15	-$0.08	+$0.07	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
MBOT Microbot Medical	N/A	N/A	N/A	N/A	N/A
OM Outset Medical	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DCTH Delcath Systems	N/A	10.88	9.87
MBOT Microbot Medical	N/A	16.19	16.19
OM Outset Medical	0.63	7.47	6.05
TMCI Treace Medical Concepts	0.55	3.52	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DCTH Delcath Systems	61.12%
MBOT Microbot Medical	16.30%
OM Outset Medical	N/A
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
DCTH Delcath Systems	17.94%
MBOT Microbot Medical	4.74%
OM Outset Medical	2.40%
TMCI Treace Medical Concepts	27.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DCTH Delcath Systems	60	34.98 million	28.71 million	Optionable
MBOT Microbot Medical	20	36.38 million	34.65 million	Optionable
OM Outset Medical	520	17.77 million	17.34 million	Not Optionable
TMCI Treace Medical Concepts	250	63.17 million	45.66 million	Optionable

MBOT, DCTH, TMCI, and OM Headlines

Recent News About These Companies

Treace Medical Concepts: Positive Q2 Earnings Call Highlights

August 12 at 10:16 PM | tipranks.com

Analysts Have Been Trimming Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target After Its Latest Report

August 12 at 3:16 AM | finance.yahoo.com

Treace Medical Concepts (NASDAQ:TMCI) Releases Earnings Results, Beats Expectations By $0.01 EPS

August 11 at 2:33 PM | marketbeat.com

UBS Group Cuts Treace Medical Concepts (NASDAQ:TMCI) Price Target to $6.50

August 10 at 3:09 PM | marketbeat.com

Arcadia Wealth Management Inc. Invests $1.76 Million in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

August 10 at 6:37 AM | marketbeat.com

Stifel Nicolaus Lowers Treace Medical Concepts (NASDAQ:TMCI) Price Target to $6.00

August 10 at 3:31 AM | americanbankingnews.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Stifel Nicolaus Issues Pessimistic Forecast for Treace Medical Concepts (NASDAQ:TMCI) Stock Price

August 9, 2025 | marketbeat.com

Treace Medical Concepts Inc (TMCI) Q2 2025 Earnings Call Highlights: Revenue Growth and ...

August 8, 2025 | uk.finance.yahoo.com

Treace Medical anticipates 7–10% revenue growth in 2025 while launching next-gen bunion solutions

August 8, 2025 | msn.com

Treace Medical Concepts, Inc. (TMCI) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Treace Medical (TMCI) Q2 Revenue Up 7%

August 7, 2025 | fool.com

Treace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Treace Medical Concepts ReportsÂ Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025

August 7, 2025 | globenewswire.com

Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study

August 5, 2025 | finance.yahoo.com

Treace Medical Concepts (TMCI) Projected to Post Quarterly Earnings on Thursday

August 5, 2025 | americanbankingnews.com

GSA Capital Partners LLP Buys Shares of 66,790 Treace Medical Concepts, Inc. (NASDAQ:TMCI)

August 4, 2025 | marketbeat.com

Analysts Set Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target at $10.52

August 4, 2025 | americanbankingnews.com

Treace Medical Concepts (TMCI) to Release Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

Legato Capital Management LLC Purchases Shares of 56,220 Treace Medical Concepts, Inc. (NASDAQ:TMCI)

July 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBOT, DCTH, TMCI, and OM Company Descriptions

Delcath Systems NASDAQ:DCTH

$11.08 +0.21 (+1.88%)

As of 02:43 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Microbot Medical NASDAQ:MBOT

$3.00 -0.13 (-4.01%)

As of 02:44 PM Eastern

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

Outset Medical NASDAQ:OM

$13.02 +0.35 (+2.76%)

As of 02:43 PM Eastern

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Treace Medical Concepts NASDAQ:TMCI

$6.94 +0.41 (+6.28%)

As of 02:43 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time